What is it about?
This study reanalyzed data from a large clinical trial to reveal the stages of polycystic kidney disease at which tolvaptan, a drug developed to treat the disease, might have the greatest effect.
Featured Image
Why is it important?
There is currently no treatment for polycystic kidney disease. The large clinical trial lumped all of the treated patients together; the results were positive and statistically significant, however, some critics the outcome is not sufficiently robust. This reanalysis found that patients with the worst kidney function had the greatest response to therapy.
Perspectives
I think this study validates the use of tolvaptan to treat polycystic kidney disease.
Dr Jared J Grantham
Kansas University Medical Center
Read the Original
This page is a summary of: Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial, Clinical Journal of the American Society of Nephrology, February 2016, American Society of Nephrology,
DOI: 10.2215/cjn.06300615.
You can read the full text:
Contributors
The following have contributed to this page
